Results 41 to 50 of about 582,473 (264)

The Relationship between Risk Levels of Breast Cancer and Use of Early Diagnosis and Screening Services in Healthcare Workers in Turkey

Iranian Journal of Public Health, 2020
Background: This study aimed to determine the factors affecting early diagnosis and screening behaviors of healthcare workers concerning breast cancer and the breast cancer risk levels using the risk identification model and to evaluate the relationship ...
Ayla ACIKGOZ, Selda YORUK, Hulya TURKMEN, Gul ERGOR   +3 more
doaj   +1 more source

Research Status of Systemic Adjuvant Therapy for Early Breast Cancer

Cancer Control, 2023
Breast cancer has surpassed lung cancer as the most common cause of cancer deaths, worldwide. Early breast cancers are treatment sensitive and patients under standardized treatment have prolonged.
Wenyu Hu, Dongdong Xu, Nanlin Li
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Partial breast irradiation for early breast cancer [PDF]

Cochrane Database of Systematic Reviews, 2014
Breast-conserving therapy for women with breast cancer consists of local excision of the tumour (achieving clear margins) followed by radiotherapy (RT). RT is given to sterilize tumour cells that may remain after surgery to decrease the risk of local tumour recurrence. Most true recurrences occur in the same quadrant as the original tumour.
Margot, Lehman, Brigid E, Hickey, Daniel P, Francis, Adrienne M, See   +3 more
openaire   +3 more sources

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Dataset of breast mammography images with masses

Data in Brief, 2020
Among many cancers, breast cancer is the second most common cause of death in women. Early detection and early treatment reduce breast cancer mortality.
Mei-Ling Huang, Ting-Yu Lin
doaj   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Disparities in stage at diagnosis among breast cancer molecular subtypes in China

Cancer Medicine, 2023
Background Disease stage at diagnosis and molecular subtypes are the main determinants of breast cancer treatment strategies and prognosis. We aimed at examining the disparities and factors associated with the stage at diagnosis among the molecular ...
Hongmei Zeng, Siqi Wu, Fei Ma, John S. Ji, Lingeng Lu, Xianhui Ran, Jin Shi, Daojuan Li, Lan An, Rongshou Zheng, Siwei Zhang, Wanqing Chen, Wenqiang Wei, Yutong He, Jie He   +14 more
doaj   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

From raw clinical data to robust prediction: an AI framework for early lymphedema detection

BMC Medical Research Methodology
Purpose Breast cancer related lymphedema (BCRL) is a frequent postoperative complication that can substantially impair physical function and quality of life. While objective detection tools such as bioimpedance spectroscopy and imaging are accurate, they
Ibrahim Sadek, Shafiq Ul Rehman, Ahmed Gehad, Esraa G. Eltasawi, Ahmed AbdelKader, Rawan Abdelnasser, Dina Nashaat, Raef Mourad Zaki, Lamees N. Mahmoud   +8 more
doaj   +1 more source